Breast cancer is not a single disease. It exists in distinct molecular subtypes, each with different biology, behavior, and response to treatment. That complexity is exactly why choosing the right cell line matters so much in drug screening research.
The cell lines you select will shape your results, influence your conclusions, and determine how relevant your findings are to real patients. This guide covers the ten most widely used human breast cancer cell lines in drug discovery, what each one represents, why researchers rely on it, and what it is best suited for.
Why Breast Cancer Cell Lines Matter in Drug Screening
Before a potential drug reaches a clinical trial, it has to prove itself in the lab. Breast cancer cell lines provide the first test. They let researchers measure how a compound affects cancer cell growth, survival, and gene expression, at scale, with consistency, and without the ethical and logistical challenges of patient tissue.
The key is matching the cell line to the question. A cell line from an estrogen receptor-positive tumor behaves very differently from a triple-negative line. Using the wrong model can generate misleading data about drug efficacy or toxicity.
Understanding what each line represents, its receptor status, molecular subtype, and known mutations, is the foundation of well-designed breast cancer research.
Breast Cancer Subtypes and Their Cell Line Models
Human breast cancer is commonly classified by the expression of three receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This gives us four main subtypes used in research:
- Luminal A — ER+/PR+, HER2−, typically lower grade
- Luminal B — ER+/PR+, HER2+ or high Ki-67
- HER2-enriched — HER2 overexpressed, ER−/PR−
- Triple-negative (TNBC) — ER−/PR−/HER2−, most aggressive subtype
Each subtype has well-established cell line models used across thousands of published studies.
The Top 10 Breast Cancer Cell Lines for Drug Screening
1. MCF-7 — The Standard ER-Positive Model
MCF-7 is the most referenced breast cancer cell line in published research. It is ER-positive, PR-positive, and HER2-negative — making it the go-to model for luminal A breast cancer.
It is widely used for hormone receptor studies, tamoxifen and aromatase inhibitor research, and understanding estrogen-driven cell proliferation. Its decades-long track record means there is extensive baseline data to compare against.
Best for: ER+ drug testing, hormonal therapy response, cell proliferation assays
2. MDA-MB-231 — The Triple-Negative Invasion Model
MDA-MB-231 is one of the most aggressive and invasive breast cancer cell lines available. It is triple-negative (ER−/PR−/HER2−) and classified as claudin-low, a particularly metastasis-prone subtype.
This cell line is widely used to study tumor invasion, migration, and metastatic potential. It also serves as a standard model for testing drugs targeting TNBC, which remains the subtype with the fewest approved targeted therapies.
Best for: TNBC drug screening, invasion and migration assays, metastasis research
3. T-47D — Luminal A with Distinct Metabolic Profile
T-47D is an ER-positive, PR-positive, HER2-negative cell line that pairs well with MCF-7 in luminal A studies. While it shares receptor status with MCF-7, it has a notably different metabolic profile — lower mitochondrial activity and distinct responses to some chemotherapy agents like paclitaxel.
Researchers use it to validate findings from MCF-7 or to study how the same receptor-positive phenotype can respond differently to treatment.
Best for: Comparative ER+ studies, hormone therapy research, metabolic profiling
4. SK-BR-3 — The Primary HER2-Amplified Model
SK-BR-3 is ER-negative, PR-negative, and strongly HER2-overexpressing — the standard in vitro model for HER2-enriched breast cancer. It is used extensively in research on anti-HER2 therapies including trastuzumab and lapatinib.
Its well-characterized HER2 amplification and sensitivity profile make it essential for any study evaluating compounds targeting the HER2 pathway.
Best for: HER2-targeted drug screening, trastuzumab resistance studies, HER2 signaling research
5. BT-474 — HER2+ with Hormone Receptor Co-expression
BT-474 is unique in that it is both HER2-amplified and ER-positive — representing luminal B breast cancer with HER2 overexpression. This makes it particularly valuable for studying the interplay between HER2 signaling and estrogen receptor pathways.
It is also used in trastuzumab response studies and for modeling the subset of patients whose tumors express multiple receptors simultaneously.
Best for: HER2+/ER+ combination therapy research, luminal B modeling, trastuzumab response
6. MDA-MB-468 — Basal-Like TNBC with EGFR Expression
MDA-MB-468 represents basal-like TNBC and is notable for its high expression of EGFR (epidermal growth factor receptor) and loss of PTEN. These characteristics make it a relevant model for studying EGFR-targeted therapies and PI3K pathway inhibitors in triple-negative disease.
It also shows distinct responses to chemotherapy compared to MDA-MB-231, making it a useful complement when building a TNBC screening panel.
Best for: EGFR inhibitor studies, basal-like TNBC research, PI3K pathway analysis
7. ZR-75-1 — ER-Positive with High Hormonal Sensitivity
ZR-75-1 is an ER-positive, PR-positive cell line derived from a breast cancer ascites. It has particularly high sensitivity to estrogen-driven proliferation, making it useful for studying the detailed mechanisms of hormone receptor signaling.
It is frequently included alongside MCF-7 and T-47D in multi-cell-line ER+ studies, adding biological breadth when testing hormonal therapies or endocrine disruptors.
Best for: Hormonal sensitivity studies, ER signaling research, comparative luminal panels
8. HCC1937 — The BRCA1-Mutant TNBC Model
HCC1937 is one of the few commercially available breast cancer cell lines derived from a patient with a confirmed germline BRCA1 mutation. This makes it an essential model for hereditary breast cancer research and for studying PARP inhibitor response — a class of drugs that specifically targets BRCA-deficient tumors.
For researchers working on DNA repair mechanisms or precision oncology approaches to TNBC, HCC1937 is difficult to replace.
Best for: BRCA1-mutant drug testing, PARP inhibitor research, hereditary breast cancer modeling
9. BT-20 — An Early-Passage Basal Model
BT-20 is one of the older established breast cancer cell lines and is classified as basal-like and triple-negative. It carries wild-type BRCA1 and has distinct epigenetic characteristics that differentiate it from other TNBC lines.
It is used in studies examining basal breast cancer biology, chemotherapy sensitivity, and as part of broader cell line panels when researchers want coverage across different TNBC subtypes.
Best for: Basal-like TNBC panel studies, epigenetic research, chemotherapy response profiling
10. 4T1 — The Mouse Model for In Vivo Translation
4T1 is a murine breast cancer cell line — the only mouse line in this list — and it is included for good reason. It closely mimics stage IV human breast cancer and can spontaneously metastasize to the lung, liver, bone, and brain in immunocompetent BALB/c mice.
This makes 4T1 uniquely valuable for syngeneic in vivo studies where researchers need an intact immune system. For immunotherapy and combination drug testing where immune response matters, 4T1 is the most commonly used model.
Best for: Syngeneic tumor models, immunotherapy research, in vivo metastasis studies
How to Choose the Right Breast Cancer Cell Line
No single cell line captures the full biology of breast cancer. The best approach is to match your cell line selection to your specific research question:
- Testing a hormonal therapy? Start with MCF-7 and validate with T-47D or ZR-75-1.
- Studying anti-HER2 compounds? SK-BR-3 and BT-474 should be your primary models.
- Working on TNBC? Build a panel — MDA-MB-231 for invasion, MDA-MB-468 for EGFR biology, HCC1937 for BRCA1-mutant response.
- Need immune-intact in vivo data? 4T1 is the standard choice
Using multiple cell lines that represent different subtypes gives you more confidence that your findings are not model-specific artifacts.
Frequently Asked Questions
What is the most commonly used breast cancer cell line?
MCF-7 is the most widely used breast cancer cell line globally, appearing in more published studies than any other. It represents ER-positive, luminal A breast cancer and has been in use for decades.
What breast cancer cell lines are used for triple-negative breast cancer research?
MDA-MB-231, MDA-MB-468, HCC1937, and BT-20 are among the most commonly used TNBC cell lines. MDA-MB-231 is particularly popular for invasion and metastasis studies, while HCC1937 is the primary model for BRCA1-mutant TNBC.
What is the difference between ER-positive and triple-negative breast cancer cell lines?
ER-positive cell lines such as MCF-7 and T-47D express the estrogen receptor and respond to hormonal therapies. Triple-negative cell lines lack ER, PR, and HER2 expression, making them harder to treat with targeted agents and more relevant for chemotherapy and immunotherapy research.
Which breast cancer cell line is best for HER2-targeted drug testing?
SK-BR-3 is the most widely used for HER2-targeted drug screening due to its strong HER2 amplification and established sensitivity profiles. BT-474, which is HER2+/ER+, is commonly used alongside it to study HER2 therapy in hormone receptor co-expressing tumors.
What is the 4T1 breast cancer cell line used for?
4T1 is a murine breast cancer cell line used primarily for in vivo syngeneic tumor studies. Because it grows in immunocompetent mice and spontaneously metastasizes, it is the preferred model for testing immunotherapies and studying the tumor immune microenvironment.
Final Thought
The breast cancer cell lines described here are not interchangeable. Each one was derived from a specific tumor, in a specific patient, at a specific stage, and those origins shape how the cells behave in your experiments.
Understanding the biology behind each line is just as important as the experimental design itself. Match the model to the question, use panels where possible, and always source authenticated, quality-controlled cells from a reliable supplier.